UBS Group
BBNX

UBS Group’s Beta Bionics BBNX Stock Holding History

UBS Group’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.06M Sell
386,623
-236,630
-38% -$2.81M ﹤0.01% 3958
2026
Q1 		$6.24M Buy
623,253
+371,815
+148% +$5.5M ﹤0.01% 3828
2025
Q4 		$7.66M Buy
251,438
+123,533
+97% +$3.3M ﹤0.01% 3580
2025
Q3 		$2.54M Buy
127,905
+31,844
+33% +$560K ﹤0.01% 4733
2025
Q2 		$1.4M Sell
96,061
-28,279
-23% -$400K ﹤0.01% 5149
2025
Q1 		$1.52M Buy
+124,340
New +$2.32M ﹤0.01% 4921

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

UBS Group's BBNX Position: Q2 2026 in Review

UBS Group reduced its Beta Bionics (BBNX) stake by 38% in Q2 2026, selling an estimated $2.81M and leaving 386,623 shares worth $6.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3958.

UBS Group first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $7.66M in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • UBS Group held 386,623 shares of Beta Bionics worth $6.06M as of Q2 2026.
  • UBS Group sold 236,630 Beta Bionics shares in Q2 2026, an estimated $2.81M.
  • Beta Bionics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3958 holding.
  • UBS Group first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • UBS Group's Beta Bionics position peaked at $7.66M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.